New Tool Estimates Breast Cancer Recurrence Risk
The FDA-cleared software uses AI to help patients with common breast cancer subtypes understand their recurrence risk.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Would you trust an AI-generated score to help guide your breast cancer treatment planning?
The FDA has cleared the TumorSight Risk software, an AI-based tool designed to estimate breast cancer recurrence risk for patients with hormone receptor-positive and HER2-negative disease. This technology is intended to help oncologists tailor treatment plans for individuals facing the most common form of breast cancer in the U.S.
Why it matters
By providing a standardized recurrence risk score, this software aims to give oncologists clearer insights for treatment decisions in the 75% of U.S. breast cancer cases that are HR+/HER2-. It offers a data-driven approach to understanding individual prognosis beyond traditional staging.
A validation study of 2,129 patients confirmed that the tool identifies significant differences in recurrence risk, with high-risk patients showing a 3.3-fold greater likelihood of recurrence than low-risk individuals. The study results were presented at the 2026 American Society of Clinical Oncology Annual Meeting.
The players
SimBioSys
A health technology company that develops AI-powered software for precision oncology and cancer care planning.
American Society of Clinical Oncology
A professional organization for physicians and oncology professionals that establishes evidence-based standards for cancer care.
Mayo Clinic
A nonprofit academic medical center and health system that conducts large-scale clinical and translational research.
Stanford Medicine
An academic health system that advances medical research and integrates clinical trials into standard cancer practice.
The details
TumorSight Risk uses artificial intelligence to analyze a patient’s specific breast MRI scans, pathology reports, and clinical data. By examining tumor characteristics alongside the context of the surrounding breast tissue, the platform assigns a score between zero and 100 to estimate the likelihood of recurrence over five and 10 years. This score provides oncologists with a quantitative metric to supplement standard clinical evaluation for patients with Stage I to IIIA HR+/HER2- breast cancer.
Timeline
2026: Study results were presented at the American Society of Clinical Oncology Annual Meeting.
Health Landscape
This development reflects an ongoing shift toward integrating artificial intelligence into oncology to personalize treatment strategies. It builds upon findings shared at the American Society of Clinical Oncology Annual Meeting, moving toward more precise risk stratification tools.
Patients with HR+/HER2- breast cancer may want to ask their oncologist if recurrence risk assessment software is part of their clinical evaluation process. This tool is designed to provide supplemental data for treatment planning, and it is worth discussing with your physician how such scores may affect your care path.
The takeaway
AI tools are becoming a common fixture in cancer care by helping doctors interpret complex tissue and imaging data. If you have been diagnosed with breast cancer, talk to your oncology team about the specific tests used to determine your risk of recurrence and what those results mean for your treatment.
Further reading
For more information on current treatment standards, visit Cancer.
Source note: This article includes information reported by Mint.
Live Poll
Would you trust an AI-generated score to help guide your breast cancer treatment planning?
